Lineage, Inc. (LINE) AI Stock Analysis

• Market Cap: $9.01B
• Dividend Yield: 5.36%
• Average Volume (3M): 1.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.29
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 26,000
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Industrial
• EPS (TTM): -0.03
• Shares Outstanding: 228,767,620
• 10 Day Avg. Volume: 862,718
• 30 Day Avg. Volume: 1,104,597
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.07
• Enterprise Value/Revenue: 3.51
• Enterprise Value/Gross Profit: 11.97
• Enterprise Value/Ebitda: 34.48
• 1Y Price Target: $46.14
• Price Target Upside: 17.11% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14

• Rating: 53 Neutral
• Price Target: $41.00 ▲(4.06% Upside)

Lineage, Inc.'s overall stock score reflects a combination of stable revenue and operational cash flow but significant challenges in profitability and valuation. The technical indicators suggest a neutral trend, while the earnings call highlighted both strategic achievements and financial challenges. The high dividend yield provides some investor appeal, but the negative P/E ratio and reduced guidance weigh heavily on the score.

Positive Factors

Productivity Improvements

The successful implementation of LinOS, with significant productivity gains, indicates operational efficiency improvements, which can enhance profitability and competitiveness in the long term.

Strategic Partnerships

Strategic partnerships and acquisitions expand Lineage's market reach and capabilities, positioning it well for sustained growth and innovation in the regenerative medicine sector.

Investment-Grade Bond Offering

The successful bond offering enhances Lineage's financial flexibility, providing capital for growth initiatives and strengthening its balance sheet over the long term.

Negative Factors

Reduced Annual Guidance

The reduction in annual financial guidance reflects ongoing market challenges, potentially impacting investor confidence and the company's ability to meet long-term financial targets.

Decreased Adjusted EBITDA

A decrease in EBITDA suggests operational challenges and cost pressures, which could hinder profitability and limit reinvestment capacity for future growth.

Decline in Same Warehouse NOI

The decline in same warehouse NOI indicates inefficiencies or reduced demand, which could affect the company's ability to maintain stable cash flows and operational performance.

Lineage, Inc. Business Overview & Revenue Model

Company Description

Lineage, Inc. (LINE) is a biotechnology company focused on developing innovative solutions in the field of regenerative medicine and cellular therapies. The company operates primarily in the healthcare sector, leveraging its proprietary technologies to produce and commercialize advanced therapies aimed at treating various diseases and conditions. Lineage's core products include stem cell-derived therapies and tissue engineering solutions, with a strong emphasis on applications for spinal cord injuries, retinal diseases, and other chronic conditions.

How the Company Makes Money

Lineage, Inc. generates revenue through multiple streams, including the commercialization of its stem cell therapies and partnerships with pharmaceutical and biotechnology companies for research and development collaborations. The company often enters into licensing agreements that allow it to earn royalties on sales of products developed using its proprietary technologies. Additionally, Lineage may receive milestone payments tied to the success of clinical trials and regulatory approvals of its therapies. Strategic partnerships with academic institutions and research organizations also play a crucial role in funding its development programs, further contributing to its revenue generation.

Lineage, Inc. Financial Statement Overview

Summary

Lineage, Inc. shows stable revenue and operational cash flow but struggles with profitability and free cash flow generation. The balance sheet is moderately leveraged with a reasonable equity position, yet operational inefficiencies and negative net profit margins are concerning.

Income Statement

Lineage, Inc. has shown stable revenue over the past year, with a slight decline from the previous year. The gross profit margin is healthy at approximately 33%, but the net profit margin is negative due to significant net losses. The EBIT and EBITDA margins indicate operational challenges, with EBIT being particularly low, suggesting high operating expenses or other costs impacting profitability.

Balance Sheet

The company's balance sheet reflects a moderate debt-to-equity ratio, indicating a balanced approach to financing. However, the return on equity is negative due to net losses, which is a concern for investors. The equity ratio is around 46%, showing a reasonable level of equity financing relative to total assets.

Cash Flow

Lineage, Inc. has a positive operating cash flow, which is a good sign of operational efficiency. However, free cash flow is minimal, indicating limited cash available after capital expenditures. The operating cash flow to net income ratio is strong, but the free cash flow to net income ratio is low, reflecting challenges in generating free cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2018
Income Statement
Total Revenue	5.32B	5.34B	5.34B	4.93B	3.70B	517.82M
Gross Profit	1.56B	1.76B	1.75B	1.46B	1.13B	517.82M
EBITDA	541.00M	547.00M	452.00M	1.06B	841.00M	386.30M
Net Income	-562.00M	-664.00M	-77.00M	-62.70M	-153.30M	-140.67M
Balance Sheet
Total Assets	19.44B	18.66B	18.87B	18.56B	16.42B	2.75B
Cash, Cash Equivalents and Short-Term Investments	81.00M	173.00M	68.00M	170.60M	209.10M	89.06M
Total Debt	7.68B	6.88B	11.05B	10.69B	9.60B	1.03B
Total Liabilities	9.78B	8.97B	12.85B	12.45B	11.14B	1.25B
Stockholders Equity	8.64B	8.64B	5.05B	5.17B	4.34B	1.50B
Cash Flow
Free Cash Flow	73.00M	12.00M	30.00M	-312.00M	-359.20M	265.06M
Operating Cash Flow	582.00M	703.00M	795.10M	500.90M	329.90M	268.30M
Investing Cash Flow	-659.00M	-919.00M	-1.07B	-2.37B	-3.41B	-689.09M
Financing Cash Flow	197.00M	320.00M	136.20M	1.84B	3.03B	426.21M

Lineage, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 39.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LINE, the sentiment is Negative. The current price of 39.4 is below the 20-day moving average (MA) of 40.15, below the 50-day MA of 40.13, and below the 200-day MA of 46.77, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 47.02 is Neutral, neither overbought nor oversold. The STOCH value of 26.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LINE.

Lineage, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EGP	―	$9.31B	36.61	7.83%	3.29%	11.10%	-1.65%
REXR	―	$9.62B	29.23	4.03%	4.13%	10.27%	15.25%
STAG	―	$7.15B	29.57	7.17%	3.89%	8.56%	22.20%
TRNO	―	$5.90B	22.74	6.85%	3.48%	22.17%	40.80%
FR	―	$7.55B	30.92	8.97%	3.05%	9.66%	-23.17%
Sector *	―	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
LINE	―	$9.01B	―	-8.75%	5.36%	―	―

Lineage, Inc. Corporate Events

Lineage, Inc. Appoints New CFO and VP of Investor Relations

On October 17, 2025, Lineage, Inc. announced the appointment of Robb LeMasters as Chief Financial Officer, effective November 10, 2025, succeeding Robert Crisci who is retiring. LeMasters brings extensive experience from BWX Technologies and other financial firms, expected to drive growth and shareholder value. Additionally, Ki Bin Kim was appointed as Vice President of Investor Relations, bringing expertise from Truist Securities to strengthen investor relations and communicate the company’s strategic vision.

The most recent analyst rating on (LINE) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Lineage, Inc. stock, see the LINE Stock Forecast page.

Lineage, Inc. Balances Growth and Challenges in Latest Earnings Call

Lineage, Inc. Balances Growth and Challenges in Latest Earnings Call

Lineage, Inc. Reports Q2 2025 Financial Results

Lineage, Inc. is the world’s largest global temperature-controlled warehouse REIT, operating a vast network of facilities across North America, Europe, and Asia-Pacific, partnering with major food and beverage producers to enhance distribution efficiency and sustainability.

Lineage, Inc. Reports Q2 2025 Financial Results

On August 6, 2025, Lineage, Inc. reported its financial results for the second quarter of 2025, showing a total revenue increase of 0.9% to $1,350 million, despite a GAAP net loss of $7 million. The company experienced a 55.1% increase in AFFO, though adjusted EBITDA decreased by 2.4%. Lineage completed a $500 million bond offering and declared a quarterly dividend of $0.5275 per share. Due to muted seasonal inventory levels, the company lowered its full-year 2025 guidance, focusing on revenue growth and operational efficiency to prepare for industry recovery.

The most recent analyst rating on (LINE) stock is a Buy with a $102.00 price target. To see the full list of analyst forecasts on Lineage, Inc. stock, see the LINE Stock Forecast page.